Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652

References

• Hui R, Garon EB, Goldman JW, et al. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Ann Oncol. 2017;28(4):874–881.
   PubMed Web of Science ®Google Scholar
• Haag GM, Zoernig I, Hassel JC, et al. Phase II trial of ipilimumab in melanoma patients with preexisting humoral immune response to NY-ESO-1. Eur J Cancer. 2018;90:122–129.
   PubMed Web of Science ®Google Scholar
• Brignone C, Escudier B, Grygar C, et al. A phase I pharmacokinetic and biological correlative study of IMP321, a novel MHC class II agonist, in patients with advanced renal cell carcinoma. Clin Cancer Res. 2009;15(19):6225–6231.
   PubMed Web of Science ®Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Cebada J, et al. Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1. Expert Opin Ther Pat. 2019;29(5):311–314.
   PubMed Web of Science ®Google Scholar
• Perez SA, Anastasopoulou EA, Tzonis P, et al. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial. Cancer Immunol Immunother. 2013;62(10):1599–1608.
   PubMed Web of Science ®Google Scholar
• Ngiow SF, von Scheidt B, Akiba H, et al. Anti-TIM3 antibody promotes T cell IFN-?–mediated antitumor immunity and suppresses established tumors. Cancer Res. 2011;71(10):3540–3551.
   PubMed Web of Science ®Google Scholar
• Herrera-Camacho I, Anaya-Ruiz M, Perez-Santos M, et al. Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1. Expert Opin Ther Pat. 2019;29(8):587–593.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–730.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41.
   PubMed Web of Science ®Google Scholar
• Omuro A, Vlahovic G, Lim M, et al. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2017;20(5):674–686.
   Web of Science ®Google Scholar
• Triebel F, Brignone C Combined preparations for the treatment of cancer or infection. United States US 2018271940. 2018 Sep 27.
   Google Scholar
• Perez-Santos M, Anaya-Ruiz M, Cebada J, et al. LAG-3 antagonists by cancer treatment: a patent review. Expert Opin Ther Pat. 2019;29(8):343–351.
   Web of Science ®Google Scholar
• Vitale M, Cantoni C, Pietra G, et al. Effect of tumor cells and tumor microenvironment on NK-cell function. Eur J Immunol. 2014;44(6):1582–1592.
   PubMed Web of Science ®Google Scholar
• Moretta A, Pende D, Locatelli F, et al. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haematopoietic stem cell transplantation to cure highrisk leukaemias. Clin Exp Immunol. 2009;157(3):325–331.
   PubMed Web of Science ®Google Scholar
• Bao X, Hanson AL, Madeleine MM, et al. HLA and KIR associations of cervical neoplasia. J Infect Dis. 2018;218(12):2006–2015.
   PubMed Web of Science ®Google Scholar
• Falco M, Moretta L, Moretta A, et al. KIR and KIR ligand polymorphism: a new area for clinical applications? Tissue Antigens. 2013;82(6):363–373.
   PubMedGoogle Scholar
• Leone P, De Re V, Vacca A, et al. Cancer treatment and the KIR–HLA system: an overview. Clin Exp Med. 2017;17(4):419–429.
   PubMed Web of Science ®Google Scholar
• Wagtmann PA, Svendsen I, Sten R, et al. Novo Nordisk A/S, Germany. Anti-KIR antibodies, formulations, and uses thereof. United States patent US9879082. 2018 Jan 30.
   Google Scholar
• Wagtmann PA, Svendsen I, Sten R, et al. Novo Nordisk A/S, Germany. Anti-KIR antibodies, formulations, and uses thereof. United States patent US2018208652. 2018 Jul 26.
   Google Scholar
• Benson DM, Hofmeister CC, Padmanabhan S, et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood. 2012;120(22):4324–4333.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): national Library of Medicine (US). 2016 March 31. Identifier NCT00552396, An Open-label, dose-escalation safety and tolerability trial assessing anti-KIR (1-7F9) in subjects with multiple myeloma. Available from: https://clinicaltrials.gov/ct2/show/results/NCT00552396?term=KIR+antibody&cond=cancer&rank=7
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2014 Feb 28. Identifier NCT01256073, A safety and tolerability extension trial assessing repeated dosing of anti-KIR (1-7F9) human monoclonal antibody in patients with acute myeloid leukaemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01256073?term=KIR+antibody&cond=cancer&rank=8.
   Google Scholar
• Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281(1–2):65–78.
   PubMed Web of Science ®Google Scholar
• Luo X, Yu Y, Liang A, et al. Intratumoral expression of MIP-1beta induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells. Cell Mol Immunol. 2004;1(3):199–204.
   PubMed Web of Science ®Google Scholar
• Przespolewski A, Szeles A, Wang ES. Advances in immunotherapy for acute myeloid leukemia. Future Oncol. 2018;14(10):963–978.
   PubMed Web of Science ®Google Scholar
• Mills JR, Barnidge DR, Dispenzieri A, et al. High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma. Blood Cancer J. 2017;7(8):e590.
   PubMedGoogle Scholar
• Vey N, Bourhis JH, Boissel N, et al. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood. 2012;120(22):4317–4323.
   PubMed Web of Science ®Google Scholar
• Korde N, Carlsten M, Lee MJ, et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica. 2014;99(6):e81.
   PubMed Web of Science ®Google Scholar
• Carlsten M, Korde N, Kotecha R, et al. Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma. Clin Cancer Res. 2016;22(21):5211–5222.
   PubMed Web of Science ®Google Scholar
• Benson DM, Cohen AD, Jagannath S, et al. A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin Cancer Res. 2015;21(18):4055–4061.
   PubMed Web of Science ®Google Scholar
• Benson DM, Bakan CE, Zhang S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118(24):6387–6391.
   PubMed Web of Science ®Google Scholar